TARS - Company ID 0001819790
The table below shows Tarsus Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.45M | -$83.03M | -$117.49M | -$49.03M | $3.75M | -$21.14M |
| Capital expenditure | $9.86M | $1.57M | $1.50M | $506.00K | $586.00K | $456.00K |
| Investing cash flow | -$42.12M | -$199.19M | $140.60M | -$144.63M | -$586.00K | -$456.00K |
| Dividends paid | - | - | - | - |
Tarsus Pharmaceuticals, Inc. reported operating cash flow of -$12.45M for fiscal year 2025. That is up 85.0% from -$83.03M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$3.67M (FY 2019) to -$12.45M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $143.39M | $154.66M | $130.18M | $93.99M | $21.00K | $131.77M |